GENinCode UK Ltd. (GB:GENI) has released an update.
GENinCode Plc, a UK company specializing in genetic risk assessment for cardiovascular disease and ovarian cancer, will present its unaudited interim results for the first half of 2024 on September 25th. The company has scheduled an analyst briefing and a live presentation for investors on the same day, highlighting the significance of their predictive technology in preventative healthcare. Interested investors and shareholders are encouraged to engage with the event through the Investor Meet Company platform, where they can also submit questions.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
